MeSH term
Frequency | Condition_Probility | Humans | 63 | 0.0 |
Aged | 11 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Antigens, CD/analysis | 7 | 0.0 |
DNA, Viral/analysis | 2 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Immunophenotyping | 10 | 0.0 |
Male | 16 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/biosynthesis/*immunology | 2 | 40.0 |
Female | 18 | 0.0 |
Histocompatibility Antigens Class II/biosynthesis/*immunology | 2 | 50.0 |
Immunohistochemistry | 14 | 0.0 |
Pregnancy | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/biosynthesis | 2 | 6.0 |
Child | 4 | 0.0 |
Histocompatibility Antigens Class II/biosynthesis | 2 | 4.0 |
Animals | 10 | 0.0 |
Histocompatibility Antigens Class II/immunology | 2 | 1.0 |
Mice | 8 | 0.0 |
Mice, SCID | 3 | 0.0 |
Protein Binding | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 17 | 0.0 |
Time Factors | 3 | 0.0 |
Tumor Cells, Cultured | 13 | 0.0 |
Adult | 12 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 5 | 2.0 |
*Gene Expression Profiling | 2 | 0.0 |
Histocompatibility Antigens Class II/analysis | 5 | 2.0 |
Middle Aged | 11 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 27 | 0.0 |
Vimentin/analysis | 2 | 0.0 |
Amino Acid Sequence | 3 | 0.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Molecular Sequence Data | 4 | 0.0 |
Phenotype | 4 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Base Sequence | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
*Antibodies | 2 | 4.0 |
Antigens, Differentiation, B-Lymphocyte/*immunology | 2 | 2.0 |
Cell Survival | 2 | 0.0 |
Comparative Study | 6 | 0.0 |
Electrons | 2 | 6.0 |
Histocompatibility Antigens Class II/*immunology | 4 | 2.0 |
T-Lymphocytes/*immunology | 4 | 0.0 |
Antigens, CD/immunology | 2 | 0.0 |
Flow Cytometry | 6 | 0.0 |
Lymphoma, B-Cell/*immunology | 3 | 7.0 |
Neoplasm Transplantation | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Lymphoma, B-Cell/immunology | 3 | 16.0 |
*Leukemic Infiltration | 2 | 18.0 |
Skin/*pathology | 3 | 3.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Histocompatibility Antigens Class II/*analysis | 2 | 1.0 |
Antibody Specificity | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Cell Transformation, Viral | 2 | 0.0 |
Biopsy | 4 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
Antigens, Neoplasm/analysis | 3 | 0.0 |
Immunoenzyme Techniques | 6 | 0.0 |
Cell Line | 5 | 0.0 |
Genes, Suppressor | 2 | 6.0 |
Apoptosis | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Cell Division | 2 | 0.0 |
*Antigens, Differentiation, B-Lymphocyte | 3 | 20.0 |
B-Lymphocytes/*immunology | 4 | 0.0 |
Biological Transport | 2 | 0.0 |
Brefeldin A | 2 | 4.0 |
Cyclopentanes/pharmacology | 2 | 4.0 |
Adolescent | 3 | 0.0 |
HLA-DR Antigens/immunology | 2 | 0.0 |
Histiocytes/*immunology | 2 | 50.0 |
Leukemia, Hairy Cell/*immunology | 2 | 15.0 |
Paraffin Embedding | 2 | 0.0 |
Tissue Fixation | 2 | 2.0 |
In Situ Hybridization | 2 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Antigens, CD/*analysis | 5 | 0.0 |
English Abstract | 2 | 0.0 |
Frozen Sections | 3 | 3.0 |
Antigens, CD30 | 4 | 14.0 |
Antigens, Neoplasm/*analysis | 5 | 1.0 |
Biological Markers | 3 | 0.0 |
Antigens, CD15 | 2 | 6.0 |
Histological Techniques | 2 | 4.0 |
Paraffin | 2 | 4.0 |
Antigens, Differentiation/*analysis | 2 | 1.0 |
In Vitro | 2 | 0.0 |
Lymphocyte Activation | 2 | 0.0 |
Gene Expression | 2 | 0.0 |